human papillomavirus

SAN FRANCISCO (MedPage Today) -- Vaccination against human papillomavirus (HPV) significantly reduced the risk of recurrence after surgery for HPV-related cervical lesions, according to data reported here.

(University of Michigan Health System) Patients with head and neck cancer linked to high risk human papillomavirus, or HPV, have worse outcomes if they are current or former tobacco users, according to a new study from researchers at the University of Michigan Comprehensive Cancer Center.

The annual update of the CDC's adult immunization guidelines includes a new recommendation that young women 19 to 26 be immunized with either the quadrivalent human papillomavirus (HPV) vaccine or the recently approved bivalent HPV vaccine to reduce their risk of cervical cancer.

Cervarix, one of two FDA-approved vaccines against human papillomavirus (HPV), protects against infection for more than six years, researchers found.

An experimental vaccine against human papillomavirus (HPV) can produce complete responses in some patients with precancers, Dutch researchers found.

The Advisory Committee on Immunization Practices (ACIP) has advised against the routine use of the human papillomavirus vaccine (Gardasil) in boys and men, but said individual physicians should have the option to recommend the vaccine to male patients.

WASHINGTON (MedPage Today) -- The FDA approved Merck's Gardasil vaccine against human papillomavirus (HPV) for boys and men, the same day that it okayed a competing vaccine for use in females.

(University of Illinois at Chicago) A University of Illinois at Chicago study finds girls and young women do not believe the human papillomavirus vaccine protects them against other sexually transmitted infections, nor do they believe they should stop cervical cancer screening.

(American Association for Cancer Research) Although a wide spectrum of human papillomavirus is seen across the population of India, HPV-16 and HPV-18 are the most common types and a vaccination targeting these types could eliminate 75 percent of the cervical cancers in the region, according to data presented at the American Association for Cancer Research Frontiers in Basic Cancer Research Meeting.

Vaccinating boys against human papillomavirus (HPV) is unlikely to offer good value for the money, researchers said.